Q-omics provides the consensus-scored TP73-AS3 profile across patient tissues and cancer cell-line models. TP73-AS3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TP73-AS3 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, TP73-AS3 RNA expression shows 10,711 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight HNSC, BRCA, and CCRCC as cancer lineages where TP73-AS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP73-AS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP73-AS3 survival associations across molecular data types. TP73-AS3 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP73-AS3 RNA expression–survival associations across cancer types. High TP73-AS3 expression shows unfavorable associations in LGG, KIRC, KICH, CHOL and SKCM, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TP73-AS3 RNA expression.
This table summarizes TP73-AS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TP73-AS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP73-AS3 shows higher tumor expression in BRCA, KIRC, LIHC, LUAD, HNSC and THCA. The BRCA box plot shows higher TP73-AS3 RNA expression in tumor versus normal tissue (log2 FC = +0.280, t-test p < 0.001).
This table shows molecular features associated with TP73-AS3 in patient tissues and cancer cell lines. In patient samples, TP73-AS3 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
